HALO Halozyme Therapeutics, Inc.: Enterprise Value-to-Revenue Multiple

halozyme.com (HALO) - corporate logo

Halozyme Therapeutics (HALO) monetizes the ENHANZE method by converting intravenous drugs into subcutaneous injection formats. The EV/Sales trajectory demonstrates the impact of this strategy, with the current value standing at 7092.24. Growth is driven by royalties from blockbuster drugs and share buybacks. The licensing model ensures scalability with minimal costs, creating powerful operating leverage for capitalization.

HALO - Halozyme Company Value to Revenue over the range 11/23/2025 - 11/20/2026

halozyme.com - analytical breakdowns and key metrics (HALO)

- share price and expert price forecast:
- cash and cash flow indicators:
Fundamental valuation:Halozyme HALO
Manufactured product of Halozyme Therapeutics

Investors are assessing the resilience of Halozyme Therapeutics (HALO) through the lens of its ability to generate cash flow with minimal operational risks. Its monopoly position in the subcutaneous drug delivery segment and the receipt of royalties from industry behemoths ensure high revenue margins. This unlevered revenue-based valuation compares market capitalization with operating income, stripping out the impact of leverage to determine a fair multiple.

Direct competitors

Enterprise Value-to-Sales Ratio BeiGene Ltd (ONC)|Revolution Medicines Corp (RVMD) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Ascentage Pharma Group International (AAPG)|Enterprise Value-to-Revenue Ratio CG Oncology, Inc.|Enterprise Value-to-Revenue Multiple UroGen Pharma Corp URGN|EV/Sales Multiple BCAX|Personalis, Inc. - Company Value to Revenue Ratio|Erasca - Company Value to Revenue|Business Value to Revenue DCTH|YMAB: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Aura Corp|CADL: EV/Sales Multiple|ARAY - Total Company Value-to-Revenue Ratio|SLS (SELLAS Life Sciences Group, Inc.) - EV/Sales Multiple|ACTU: Business Value to Revenue|Enterprise Value-to-Revenue Ratio citiusonc.com (CTOR)|Total Company Value-to-Revenue Ratio TuHURA Biosciences|Enterprise Value-to-Revenue Ratio Protara Therapeutics TARA|Fate Therapeutics (FATE) - Enterprise Value-to-Revenue Multiple|WHWK - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple TScan Therapeutics Inc|championsoncology.com (CSBR) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio XBIT|Company Value to Revenue CVM|Company Value to Revenue Ratio OSTX (OS Therapies Incorporated)|EV/Sales Multiple RADX|ARTV: Enterprise Value to Sales Volume|EV/Sales Multiple ANL (Adlai Nortye Ltd)|VERU - Company Value to Revenue|tempesttx.com - EV/Sales Multiple|Business Value to Revenue XLO (xiliotx.com)|RENB: EV/Sales Multiple|Company Value to Revenue Mural Oncology plc|Enterprise Value-to-Revenue Ratio Kairos Pharma Inc|OKUR: Business Value to Revenue|EV/Sales Multiple GDTC|CRIS (Curis) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio apollomicsinc.com APLM|THAR: Company Value to Revenue Ratio|advanbiomed.com - EV/Sales Multiple|Business Value to Revenue GNPX (Genprex, Inc)|Calidi Biotherapeutics Inc. (CLDI) - Enterprise Value-to-Revenue Ratio|Sunshine Biopharma Inc. (SBFM) - EV/Sales Multiple|XBIO (Xenetic Bio) - EV/Sales Multiple|Salarius Pharmaceuticals Inc (SLRX) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple PPBT|EV/Sales Multiple American Oncology Network Inc (AONC)|EV/Sales Multiple BGNE (BeiGene Ltd.)|Enterprise Value-to-Revenue Coefficient CKPT (Checkpoint Therapeutics)|ELEV - Enterprise Value-to-Revenue Ratio|ICAD (iCAD Inc.) - Company Value to Revenue Ratio|Ikena (IKNA) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Notable Labs, Ltd.|Enterprise Value-to-Revenue Ratio viracta.com|MOR: Business Value to Revenue|EV/Sales Multiple NAYA|Ascentage Pharma - Company Value to Revenue Ratio